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Metastatic melanoma has historically been considered
as one of the most therapeutically challenging
malignancies. However, for the first time after decades
of basic research and clinical investigation, new drugs
have produced major clinical responses. The discov-
ery of BRAF mutations in melanoma created the first
opportunity to develop oncogene-directed therapy in
this disease and led to the development of com-
pounds that inhibit aberrant BRAF activity. A decade
later, vemurafenib, an orally available and well-
tolerated selective BRAF inhibitor, ushered in a new
era of molecular treatments for advanced disease.
Additional targets have been identified, and novel
agents that impact on various signaling pathways or
modulate the immune system hold the promise of a
whole new therapeutic landscape for patients with
metastatic melanoma. One of the major thrusts in
melanoma therapy is now focused on understanding
and targeting the network of signal transduction
pathways and on attacking elements that underlie
the tumor’s propensity for growth and chemoresis-
tance. In this article, we review the novel targeted
anticancer approaches that are under consideration in
melanoma treatment.
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INTRODUCTION
Curative treatments for patients with metastatic melanoma
remain elusive. The median survival time for melanoma
patients with metastatic disease is 8–9 months, and the 3-year
overall survival (OS) rate is less than 15% (Balch et al., 2009).
Until recently, clinical trials of chemotherapy, immunother-
apy, and biochemotherapy have failed to significantly
improve survival. Conventional chemotherapy with dacarba-
zine (DTIC) alone is associated with an objective response
rate of, at most, 15%; moreover, nearly all of these responses
are partial (Lui et al., 2007). Immune-based therapies, such as
IFN-a and IL-2, have yielded comparable response rates, but
are associated with more intense toxicities and no clear
impact on OS for the overall population of metastatic
melanoma patients (Eggermont and Schadendorf, 2009).
Therefore, there has been significant room for improvement
with regard to both efficacy and toxicity of melanoma
therapies.
Recent advances in molecular oncology have yielded new
treatment strategies that target specific molecules and path-
ways expressed in the cancer cells. One of the first
approaches of this therapeutic strategy was the development
of Herceptin (trastuzumab), a mAb, for patients with HER2-
overexpressing breast cancers (Baselga et al., 1999). A
second successful approach was the therapeutic use of a
tyrosine kinase inhibitor, imatinib, in chronic myeloid
leukemia, a disease that is characterized by a reciprocal
translocation (Philadelphia chromosome; [t(9:22)(q34; q11)]),
which constitutively activates the Abl tyrosine kinase (Mauro
et al., 2002). To date, several targeted therapies have been
approved for the treatment of malignancies such as colo-
rectal, breast, head and neck, non-small-cell lung, and renal
cell cancer.
Melanoma is a heterogeneous disease, which suggests a
richly complex etiology. Deep molecular analyses have
revealed consistent genetic patterns among different mela-
noma subtypes. For instance, 50–60% of the more common
forms of melanoma (i.e., superficial spreading) harbor BRAF
mutations. In addition, NRAS mutations are observed in
15–30% of cutaneous melanomas and are mutually exclusive
of BRAF mutations (Albino et al., 1989; Tsao et al., 2004).
Loss of tumor suppressor genes (TSGs) have also been
identified in melanoma, often accompanying mutated onco-
genes within the same tumor. Experimental studies have
shown that the cell cycle regulators, p16 and p14ARF (both
derivative products of the CDKN2A locus), are frequently
inactivated in melanomas arising on chronically exposed skin
(Sharpless and Chin, 2003). Finally, KIT alterations (mutations
and/or amplifications) are found more frequently in melano-
mas from acral, mucosal, and chronic sun-damaged sites
(Curtin et al., 2006), whereas uveal melanomas uniquely
harbor activating mutations in the a-subunit of a G protein of
the Gq family, GNAQ and GNA11 (Van Raamsdonk et al.,
2009, 2010). The clinical challenge today is whether
effective therapies can specifically target the aberrant
functionalities associated with these somatic mutations
(Figure 1).
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TARGETING SIGNALING MOLECULES IN MELANOMA
c-Kit
c-Kit is the receptor tyrosine kinase for stem cell factor.
Activation of c-KIT by ligand binding results in the stimula-
tion of the mitogen-activated protein kinase (MAPK), phos-
phatidylinositol 3-kinase (PI3K)-AKT1, and JAK-STAT
signaling pathways, thereby producing proliferative and
survival effects. c-KIT is ubiquitously expressed in mature
melanocytes, but tends to be reduced or lost in invasive or
metastatic melanoma (Natali et al., 1992). In unselected
melanomas, the proportion of tumors retaining c-KIT over-
expression is less than 3% (Curtin et al., 2006). Recent studies
reported KIT mutations in 21% of mucosal, 11% of acral, and
17% of chronic sun-damaged melanomas; if KIT amplifica-
tions are included, the rates of KIT aberrations are 39% for
mucosal, 36% for acral, and 28% for chronic sun-damaged
melanomas (Curtin et al., 2006). The mutations are frequently
located in the juxtamembrane (exons 9, 11, and 13) domain
rather than in the catalytic domain.
Before the identification of KIT mutations in melanoma,
two Phase II studies of imatinib, a tyrosine kinase inhibitor
that targets BCR-ABL, c-Kit, and platelet derived growth
factor receptor (PDGFR)-a and -b, failed to suggest any
clinical benefit (Ugurel et al., 2005; Wyman et al., 2006). In
retrospect, only a few patients enrolled into these trials would
have been expected to harbor KIT mutations based on chance
alone. Soon after the identification of KIT mutations in
melanoma, two case reports (Hodi et al., 2008; Lutzky et al.,
2008) quickly established the potential promise of KIT-
targeted therapy in these patients, and two Phase II studies
evaluating imatinib in the context of KIT-mutated metastatic
melanoma have further explored this possibility (Carvajal
et al., 2011; Guo et al., 2011). In the Carvajal trial, the
authors showed a 16% overall durable response rate (median
OS of 46.3 weeks), with the better response rates occurring in
cases with mutations affecting recurrent hotspots (c-KITK642E
or c-KITL576P) or with a mutant-to-wild type allelic ratio of
more than 1—significance measure of potential KIT depen-
dence. In the Guo trial, 43 patients were treated with 400mg
per day imatinib and experienced a median progression-free
survival (PFS) of 3.5 months with a 6-month PFS rate of
36.6%. Eighteen patients (41.9%) demonstrated shrinkage of
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Figure 1. Key pathways and therapeutic targets in melanoma. Activation of the receptor tyrosine kinase (RTK)-NRAS-BRAF-MEK-ERK signaling stream is
central in a large proportion of melanomas (mels), with BRAF and NRAS being the most commonly activated oncogenes. Upstream of RAS, KIT is amplified or
activated in a substantial fraction of melanomas from acral, mucosal (muc), and chronic sun-damaged (CSD) sites. Stimulation of the phosphatidylinositol 3-
kinase (PI3K) pathway also occurs in melanomas either through loss of PTEN or activation of AKT3. In addition, GNAQ and GNA11, which encode G-a
proteins, are preferentially mutated in ocular melanomas. Downstream effectors of the activated signaling network lead to increased transcription of survival
genes by transcription factors and heightened prosurvival signals in the mitochondria (Mito) via regulation of apoptotic proteins (red, proapoptotic; green,
prosurvival). In the nucleus, epigenetic silencing of tumor suppressor genes occurs through DNA methylation and/or histone acetylation, which are mediated by
DNA methyltransferase (DNMT) and histone deactylase (HDAC), respectively. Targeted agents listed in the light purple boxes inhibit the central pathogenetic
pathways at specific points of action and potentially have a therapeutic impact on melanoma. Ac, acetylation (of Histone, Hi); cut, cutaneous; Me, methylation
(of DNA); TF, transcription factor.
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tumor mass, and the 1-year OS rate was 51.0%. These studies
confirm the potential clinical utility of c-KIT suppression,
although the full effects require Phase III trials. Other c-KIT
inhibitors (Table 1) are currently under study. A significant
response to another receptor tyrosine kinase inhibitor,
dasatinib, has also been reported in two metastatic melano-
ma patients with the c-KITL576P mutation (Woodman et al.,
2009). Nilotinib, a second-generation tyrosine kinase inhi-
bitor of c-KIT, PDGFR, and BCR-ABL, is currently being
tested in patients with KIT-altered melanomas who are
resistant or intolerant in other tyrosine kinase inhibitors.
A randomized Phase III trial is comparing the efficacy
of nilotinib vs. dacarbazine in the treatment of metastatic
and/or inoperable melanoma harboring a KIT mutation
(NCT01028222). Although limited in numbers thus far, these
early clinical findings confirm that KIT inhibition in the
proper genetic context can be a potentially valuable
therapeutic alternative. There is some evidence that some
c-KIT mutations are more amenable to targeting with the
available drugs than others.
RAS/RAF/MAPK/ERK PATHWAY
RAS. The RAS signaling network has gained much attention
in melanoma. This signaling cascade promotes proliferation,
survival, and invasion through two distinct pathways, the
MAPK pathway and the PI3K pathway (Hocker et al., 2008).
Activation of MAPK signaling by oncogenic mutations has
been found in up to 90% of melanoma cases. Therefore,
therapies specifically aimed at the MAPK pathway compo-
nents are likely essential treatment strategy aiming to
antagonize pathogenic signal transduction pathways in
melanoma (Figure 1).
The first component found to be activated in this pathway
was NRAS (Padua et al., 1984, 1985). NRAS is mutated in
15–20% of all melanomas, with the most common change
occurring at Glutamine 61 (Brose et al., 2002). Substitutions
at this codon impair GTP hydrolysis, and thus the NRAS
protein is constitutively active (Dahl and Guldberg, 2007).
Although RAS is considered an ideal therapeutic target for
melanoma and many other cancers, specific anti-RAS
therapies have been elusive.
Farnesyltransferase inhibitors, such as tipifarnib and
lonafarnib, block RAS activation by inhibiting posttransla-
tional farnesylation of the protein, thereby preventing
translocation of RAS to the plasma membrane. This transition
to the membrane is required for RAF dimerization and further
downstream signaling (Purcell and Donehower, 2002). A
single-agent, single-arm Phase II trial of tipifarnib for patients
with metastatic disease, including those with melanoma,
showed a lack of response among the first 14 patients; this led
to early closure of the trial (Gajewski et al., 2006). Never-
theless, there is some evidence that RAS antagonism might
enhance the effectiveness of other chemotherapeutic agents
and may thus be used as part of a combination regimen.
In vitro studies using human and mouse melanoma cell lines
showed that the combination of cisplatin and lonafarnib
(SCH66336) markedly enhanced the level of cisplatin-
induced apoptosis, an effect that was associated with an
enhanced G2/M cell cycle arrest (Smalley and Eisen, 2003;
Morgillo and Lee, 2006).
More recently, Niessner et al. (2011) demonstrated that
the combination of lonafarnib and sorafenib (a nonselective
kinase inhibitor) synergistically inhibited melanoma cell
growth, significantly enhanced sorafenib-induced apoptosis,
and completely suppressed invasive tumor growth in mono-
layer and organotypic cultures, respectively. Lonafarnib did
not affect MAPK and AKT but did affect mammalian target of
rapamycin (mTOR) signaling (Niessner et al., 2011). These
findings suggest that lonafarnib may have stronger inhibitory
effects on mTOR signaling and may sensitize melanoma cells
to sorafenib-induced apoptosis. Barring the availability of
selective RAS inhibitors, this evidence suggests that partial
modulation of RAS activation with farnesyltransferase in-
hibitors may contribute efficacy in combination treatment
regimens.
RAF. The most common oncogene to be mutated in
melanoma is BRAF. Approximately 60% of all melanomas
harbor activating mutations in BRAF, making this gene a
prime therapeutic target (Davies et al., 2002). So far, over 50
distinct mutations in BRAF gene have been identified (Garnett
and Marais, 2004). The most prevalent change is the
c.T1799A transversion, which results in a p.V600E substitu-
tion (i.e., BRAFV600E; Garnett and Marais, 2004). This gain-
of-function BRAF mutation accounts for more than 90% of
the BRAF alterations described in melanoma, with alternative
point mutations at the same position (p.V600D, p.V600K,
p.V600R) contributing another 5–6% of the total (Davies
et al., 2002). The p.V600E change occurs in the CR3 domain
of BRAF and leads to constitutive activation of the down-
stream protein kinases (i.e., MEK and ERK) and heightened
proliferation of melanoma cells.
Sorafenib is a small-molecule, nonselective RAF
inhibitor that has been shown to abrogate MAPK signaling
biochemically and to harbor antimelanoma effects in vitro
(Karasarides et al., 2004). Besides RAF, sorafenib also
inhibits receptor tyrosine kinases, including the vascular
endothelial growth factor (VEGF), c-KIT, and PDGF receptors,
and the tyrosine kinase FLT3. Early clinical trials have
failed to show any activity of sorafenib as monotherapy in
patients with metastatic melanoma (Eisen et al., 2006). The
combination of sorafenib and DTIC or temozolamide was
tested in randomized trials but failed to prove any clinical
benefit for metastatic melanoma patients (Hauschild et al.,
2009).
Currently, other more selective BRAF inhibitors (SBIs) have
been developed and are currently being evaluated in clinical
trials. The first SBI to be developed in the clinical setting is
vemurafenib (PLX4032). Vemurafenib is an orally available,
potent inhibitor of BRAF with an approximately 30-fold
selectivity for the p.V600E mutated form compared with
wild-type BRAF. In the Phase I trial, there was an 80%
response rate to vemurafenib among 32 genotype-selected
metastatic melanoma patients treated at the maximum
tolerated dose of 960mg twice daily. Overall, 26 patients
showed an objective response including two complete
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Table 1. List of currently investigated targeted therapies in advanced melanoma (information obtained from
www.clinicaltrials.gov)
Target Molecular eligibility Drug Phase NCT ID Conditions
RTK ERBB4 mutation positive Lapatinib Phase II NCT01264081 Unresectable metastatic melanoma
RTK KIT alteration present Nilotinib Phase II NCT01099514 Unresectable metastatic melanoma with KIT aberration
RTK KIT alteration present Sunitinib Phase II NCT00631618 Unresectable metastatic melanoma
RTK KIT alteration present Nilotinib Phase II NCT00788775 Unresectable metastatic melanoma, which failed
other TKIs
RTK KIT alteration present Nilotinib Phase II NCT01168050 Unresectable metastatic melanoma
RTK KIT alteration present Sunitinib Phase II NCT00577382 Unresectable metastatic mucosal, acral/lentiginous
melanoma
RTK KIT mutation of exon 9, 11, 13, or exon 17
(Y822D and mutations D820Y, Y823D)
Nilotinib vs. dacarbazine Phase III NCT01028222 Unresectable metastatic melanoma
RTK (c-Kit
selective)
KIT juxtamembrane mutation Masitinib vs. dacarbazine Phase III NCT01280565 Unresectable metastatic melanoma
TK KIT alteration present Imatinib mesylate Phase II NCT00470470 Unresectable metastatic melanoma
TK BRAF mutation positive Lenvatinib (E7080) Phase II NCT01136967 Unresectable metastatic melanoma
TK KIT mutations of exon 11 or 13 Dasatinib Phase II NCT01092728 Unresectable metastatic melanoma
BRAF BRAF V600E- or V600K-mutation positive GSK2118436 Phase II NCT01266967 Unresectable metastatic melanoma to the brain
BRAF+MEK BRAF mutation positive GSK2118436+GSK1120212 Phase I NCT01072175 Unresectable metastatic melanoma
BRAF BRAF V600E mutation positive GSK2118436 vs. dacarbazine Phase III NCT01227889 BRAF mutant unresectable metastatic melanoma
BRAF BRAF V600 mutation positive RO5212054 (PLX3603) Phase I NCT01143753 Colorectal cancer, malignant melanoma
BRAF BRAF V600 mutation positive Vemurafenib Phase II NCT01378975 Unresectable metastatic melanoma (brain metastases)
BRAF BRAF V600E mutation positive Vemurafenib Phase III NCT01307397 Unresectable metastatic melanoma
BRAF+MEK BRAF V600 mutation positive Vemurafenib+GDC-0973 Phase I NCT01271803 Unresectable metastatic melanoma
MEK BRAF WT Docetaxel+selumetinib (AZD6244);
docetaxel+placebo
Phase II NCT01256359 Unresectable metastatic melanoma
MEK BRAF V600E- or V600K-mutation
positive
GSK1120212 vs. dacarbazine or
paclitaxel
Phase III NCT01245062 BRAF mutant unresectable metastatic melanoma
MEK BRAF V600E or NRAS mutation
positive
MEK162 Phase II NCT01320085 BRAF or NRAS mutant unresectable metastatic
melanoma
MEK BRAF V600E- or V600K-mutation
or a NRAS mutation (codons 12, 13,
or 61) positive
Selumetinib (AZD6244) Phase II NCT00866177 Unresectable metastatic melanoma
MEK No GNAQ/GNA11 restrictions Selumetinib (AZD6244) vs.
temozolomide
Phase II NCT01143402 Unresectable metastatic uveal melanoma
MEK BRAF V600E mutation positive TAK-733 Phase I NCT00948467 Unresectable metastatic melanoma
CDK CDK4 mutation or amplification PD 0332991 Phase II NCT01037790 Advanced cancers
mTOR BRAF V600E mutation positive Temsirolimus+selumetinib
(AZD6244)
Phase II NCT01166126 Unresectable metastatic melanoma
RTK (c-MET) No restrictions ARQ197+sorafenib Phase I NCT00827177 Advanced cancers
RTK (VEGFR
and c-MET)
No restrictions Cabozantinib Phase II NCT00940225 Advanced cancers
RTK No restrictions Pazopanib+paclitaxel Phase II NCT01107665 Unresectable metastatic melanoma
RTK No restrictions Sunitinib Phase II NCT01216657 Chemorefractory melanoma
RTK No restrictions Sunitinib+cisplatin+tamoxifen Phase II NCT00489944 High-risk ocular melanoma
RTK No restrictions Sunitinib+dacarbazine Phase I/II NCT00859326 Unresectable metastatic melanoma
RTK No restrictions Sunitinib+hydroxychloroquine Phase I NCT00813423 Chemorefractory melanoma
TK No restrictions Lenvatinib (E7080)+dacarbazine Phase I/II NCT01133977 Unresectable metastatic melanoma
RAF No restrictions RAF265 Phase I NCT00304525 Unresectable metastatic melanoma
RAF No restrictions XL281±famotidine Phase I NCT00451880 Advanced cancers
RAF (and other
kinases)
No restrictions Sorafenib+cisplatin+tamoxifen Phase II NCT00492505 High-risk stage III melanoma
RAF (and other
kinases)
No restrictions Sorafenib vs. placebo Phase II NCT01377025 Unresectable metastatic uveal melanoma
MEK No restrictions RO4987655 Phase I NCT00817518 Advanced cancers
CDK No restrictions Dinaciclib Phase I/II NCT01026324 Unresectable metastatic melanoma
PI3K+MEK No restrictions BKM120+MEK162 Phase I/II NCT01363232 Unresectable metastatic melanoma
PI3K/mTOR+MEK No restrictions BEZ235+MEK162 Phase I/II NCT01337765 Unresectable metastatic melanoma
Abbreviations: CDK, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase; RTK, receptor tyrosine kinase;
TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor; WT, wild type.
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responses (Flaherty et al., 2010). The estimated median PFS
among all patients was greater than 8 months. The impact of
vemurafenib on OS has been recently evaluated in a Phase III
trial comparing vemurafenib with dacarbazine in 675
patients with previously untreated, metastatic melanoma
harboring the BRAFV600E mutation. At 6 months, OS was
84% in the vemurafenib group and 64% in the dacarbazine
group. In the interim analysis for OS and final analysis for
PFS, vemurafenib was associated with a relative reduction of
63% in the risk of death (Po0.001) and of 74% in the risk of
either death or disease progression (Po0.001), as compared
with dacarbazine (Chapman et al., 2011).
A rather novel side effect noted with vemurafenib was the
development of keratoacanthomas (KA) and invasive squamous
cell carcinoma (SCC), which may be due to compensatory
signaling through RAS/CRAF (Heidorn et al., 2010). Although
these tumors can be easily recognized and treated, the
surveillance strategy could be more complex in the adjuvant
setting if duration of treatment becomes more of an issue.
There are several additional BRAF inhibitors in clinical
development. GSK2118436 is an SBI with a 4100-fold
selectivity for cell lines that harbor BRAFV600E mutation. Early
results of a Phase I clinical trial have been recently reported
(Kefford et al., 2010). The response rate was comparable to
vemurafenib even before the maximum tolerated dose was
defined. Notably, 8 of 10 patients with asymptomatic brain
metastases exhibited a partial response to GSK2118426. A
Phase II study has been designed to assess the efficacy of
GSK2118436 administered to patients with BRAFV600E/V600K
mutation-positive metastatic melanoma to the brain
(NCT01266967).
Despite the vanguard studies that therapeutically validated
BRAF inhibition, there were also several challenges—
complete responses were rare, occasional patients were
refractory to treatment, and most cases ultimately relapsed
through secondary resistance. An elucidation of the mechan-
isms underlying resistance to vemurafenib has emerged as a
major research objective. Unlike imatinib in KIT-mutated
gastrointestinal stromal tumor, in which secondary mutations
in the target account for acquired resistance, no gatekeeper
BRAF mutations have been identified in melanoma patients
with acquired resistance to vemurafenib (Nazarian et al.,
2010). However, there are early studies that show compen-
satory activation of NRAS or upregulation of PDGFR-b
(Nazarian et al., 2010), induction of insulin-like growth
factor (Villanueva et al., 2010), and activation of MEK1
(Wagle et al., 2011). In a genome-wide screen, overexpres-
sion of CRAF and COT1 also appears to render cells resistant
to BRAF inhibitors (Johannessen et al., 2010).
MEK. MEK kinases lie immediately downstream of BRAF and
have been considered another important target, particularly
in the setting of activating BRAF mutations. Several MEK
inhibitors have been tested in clinical trials in patients with
metastatic melanoma. AZD6244 is a selective, non-ATP
competitive inhibitor of MEK1 and MEK2 that has been
subjected to Phase I/II trials (Adjei et al., 2008; Haura et al.,
2010). In the Phase II trial of AZD6244 for patients with
BRAFV600E-mutated melanoma, 12% of the patients experi-
enced significant, but incomplete, regression. This relatively
modest activity was reproduced in a larger randomized Phase
II study comparing AZD6244 with temozolamide; in this trial,
the AZD6244 arm did not show any significant benefit in
terms of response rates or impact on PFS (Dummer et al.,
2008), although five of six responding patients had
BRAFV600E-mutated tumors.
On a molecular level, it has been shown that MEK
inhibitors achieve much of their apoptotic effect through
suppression of the anti-apoptotic Bcl-2 member, Mcl-1, and
that melanoma lines that are resistant to MEK inhibitors
do not experience Mcl-1 suppression in response to MEK
inhibitors (Wang et al., 2007). Thus, as is the case with other
genes in the MAPK pathway, a better understanding of the
cross-talk that occurs with the Bcl-2 apoptotic network will
likely be crucial in the development of rational treatment
regimens involving MEK inhibitors.
The fact that restoration of MEK signaling is sufficient to
confer resistance to BRAF inhibitors raises the intriguing
question as to whether MEK inhibitors can be used to
overcome resistance to SBIs. Studies are under way to clinically
test this approach, including the combination of a MEK
inhibitor (GSK1120212) and a BRAF inhibitor (GSK2118436)
in a Phase II study involving patients with BRAFV600E tumors
(NCT01072175); early evidence suggests that this combination
may yield fewer SCCs/KAs and skin eruptions compared with
each agent alone (Infante et al., 2011). There is also another
trial testing the co-inhibition of both MAPK and PI3K/AKT
pathways by MEK inhibitor AZD6244 and AKT inhibitor
MK2206 in patients with BRAFV600E melanomas who pre-
viously failed an SBI (NCT01021748).
The PI3K pathway
PI3K is a downstream effector of RAS and the lead-off enzyme
for another arm of the RAS pathway. PI3K phosphorylates a
second messenger, phospatidylinositol-4,5-biphosphate,
thereby generating phospatidylinositol-3,4,5-triphosphate,
which in turn leads to activation of the pathway’s major
downstream effector, AKT. Activated AKT has several
different enzymatic substrates, including Hdm2, NF-kB,
mTOR, and p27—all of which promote cell growth and
survival. This pathway is negatively regulated by the PTEN
protein. At the molecular level, PTEN downregulates PI3K
signaling by dephosphorylating phospatidylinositol-3,4,5-
triphosphate, thereby inducing cell cycle arrest and apoptosis
(Damen et al., 1996).
Although alterations in the PI3K pathway have been
reported in up to 60% of cutaneous melanomas (Zhou et al.,
2000), attempts to therapeutically extinguish either PI3K or
AKT have not been forthcoming, given the lack of robust
clinically relevant inhibitors against these targets. Thus,
investigators have focused on downstream targets such
mTOR (Kumar et al., 2001). Recently, a series of rapamycin
analogs have been synthesized and evaluated for use in
melanoma, such as temsirolimus (CCI-779) and everolimus
(RAD001). A Phase II trial of temsirolimus was terminated
after only one objective response among 33 melanoma
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patients was observed. In addition, no objective responses
were recorded in a Phase II trial of everolimus in patients with
metastatic melanoma, although 7 of 20 patients enrolled in
the study were progression-free at 16 weeks (Rao et al.,
2006).
Tsao et al. (2004) found genetic evidence for cooperativity
between BRAF mutagenesis and PTEN inactivation, indicat-
ing a need to simultaneously activate MAPK and PI3K
pathways, respectively; this interaction has been substan-
tiated in an animal model of melanoma (Dankort et al.,
2009). It has also been shown that the combination of
sorafenib or MEK inhibitors (U0126 or PD98059) and
rapamycin potentiated growth inhibition in melanoma cell
lines. Moreover, sorafenib in combination with rapamycin
completely suppressed invasive melanoma growth in orga-
notypic cultures. These effects were associated with complete
downregulation of the anti-apoptotic proteins Bcl-2 and
Mcl-1. A Phase I/II study is currently underway testing
temsirolimus in combination with sorafenib in stage III/IV
melanoma (NCT00349206).
Werzowa et al. (2011) has also studied the effect of
targeting the PI3K/mTORC1/mTORC2 pathway by PI-103 (an
inhibitor of PI3K class IA and mTORC1/ mTORC2) and
rapamycin. In cultured melanoma cells and in a human
melanoma xenograft model, PI-103 induced apoptosis and
cell cycle arrest, and suppressed the viability of melanoma
cells in vitro. In vivo, the combination of PI-103 and
rapamycin significantly reduced the tumor growth compared
with both agents independently. These data support dual
targeting of the PI3K/mTORC1/mTORC2 pathway to max-
imize suppression. Newer inhibitors that inhibit both PI3Kand
mTOR (XL765) have also proved to be well tolerated in Phase
I studies (Papadopoulos et al., 2008). It remains to be
determined whether targeting PI3K, AKT, or mTOR will result
in a single-agent activity in any subset of melanoma, or
whether efficacy can only be observed when targeting this
pathway in conjunction with others, particularly the MAP
kinase pathway.
Restoring tumor suppression function
Epigenetic events in cancer development have attracted
much attention. This refers to any changes in gene expression
without alteration of the DNA sequence. Epigenetic silencing
has been shown to functionally inactivate several TSGs
including PTEN, CDKN2A, and APAF-1. For example,
whereas mutations and deletions of PTEN have been
observed in up to 60% of melanoma cell lines, only about
10% of uncultured samples contain genetic alterations. These
observations have led to speculations that PTEN inactivation
may predominantly occur through epigenetic programs. Two
particular mechanisms of gene regulation that have under-
gone therapeutic manipulation include DNA methylation and
histone modification. DNA methylation is mediated by DNA
methyltransferases (DNMTs), which are responsible for the
formation of a covalent attachment of a methyl group to
cytosine residues at CpG dinucleotides. Aberrant hyper-
methylation of TSGs likely contributes to tumor promotion
(Herman and Baylin, 2003). As the promoter must be
re-methylated during each cycle of DNA replication (Herman
and Baylin, 2003), DNMT inhibitors can be used to
nonselectively reactivate TSGs. One such DNMT inhibitor,
5-aza-20-deoxycytidine (decitabine), is currently approved for
patients with myelodysplastic syndrome. DNMT inhibitors
have also shown some promise in melanoma. Decitabine has
been safely administered with high-dose IL-2 and appears to
enhance the activity of IL-2 with reported objective responses
in 31% of melanoma patients (Gollob et al., 2006).
The primary enzyme responsible for histone modification
is histone deactylase (HDAC). HDAC inhibitors are also
currently being studied as a possible treatment against
melanoma. In the M14 human melanoma cell line, valproate,
an HDAC inhibitor, has been shown to induce p16INK4a and
a dose-dependent G0/G1 phase arrest, apoptosis, and
sensitization to cisplatin and etoposide (Valentini et al.,
2007). Melanoma patients are eligible for an ongoing trial
with the HDAC inhibitor, vorinostat (NCT006670820).
Unlike the more genetically precise targeted treatments,
both DNMT and HDAC inhibitors restore gene expression,
including TSGs, but in a nonspecific manner. Thus, cells with
evidence of deleterious injury at TSG loci would probably not
benefit from these agents. Moreover, the effects of non-
selective re-induction of genes may yield unpredictable
phenotypes.
Targeting apoptosis
Therapeutic agents that target the apoptotic pathways have
also been widely analyzed. It has been shown that the
overexpression of a number of anti-apoptotic proteins, such
as Bcl-s, Bcl-xL, and Mcl-1, may lead to resistance to
chemotherapy. Oblimersen is an 18-base antisense agent that
targets Bcl-2. An international randomized controlled trial of
771 melanoma patients comparing DTIC and oblimersen
with DTIC alone resulted in a higher and durable objective
response rate, an increased median PFS, but no significant
difference in OS (Bedikian et al., 2006). It was never
adequately established that this agent modulated Bcl-2
sufficiently to render cells more susceptible to cytotoxicity
(Jansen et al., 2000).
Another therapeutic target is Bcl-xL, a molecule that is
considered to serve many of the same functions as Bcl-2.
Tumor cells are able to switch expression from Bcl-2 to Bcl-
xL and, in many cases, Bcl-2 and Bcl-xL are expressed in a
reciprocal manner (Han et al., 1996; Arriola et al., 1999).
Encouraging early human studies have simultaneously
targeted Bcl-xL and other anti-apoptotic Bcl-2 family
members using small-molecule inhibitors such as obatoclax
(Nguyen et al., 2007; Wolter et al., 2007). Mcl-1 is a
structurally distinct member of the anti-apoptotic Bcl-2
family, is strongly expressed at all stages of disease (Tang
et al., 1998; Leiter et al., 2000), and is highly selective for
BAK inhibition (Zhai et al., 2008). Nguyen et al. (2007) found
that obatoclax disrupted the interaction between MCL-1 and
BAK in intact mitochondrial outer membrane and in intact
cells, and overcame MCL-1-mediated resistance to both Bcl-2
inhibitor ABT-737 and the proteasome inhibitor bortezomib.
Thallinger et al. (2003) showed that the combination of DTIC
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plus antisense oligonucleotide against Mcl-1-sensitized mel-
anomas to DTIC in a SCID mouse model. Recent data have
also shown that MEK inhibitors achieve much of their
apoptotic effect through Mcl-1 suppression (Wang et al.,
2007). Taken together, these data suggest that dual MEK/Mcl-
1 inhibition could be an effective means of improving clinical
response.
As p53 is preserved but functionally inactivated by
p14ARF loss in melanoma, restoration of p53 function
represents another attractive means of throwing the switch
from cytostasis to cytotoxicity. Ji et al. (2011) demonstrated
that Hdm2 antagonism using nutlin-3 strongly induced p53
protein and activity levels in melanoma cells, reduced
viability in vitro, and enhanced apoptosis in cell lines treated
with a MEK inhibitor.
Targeting angiogenesis
Angiogenesis is an essential process in the development of
most human tumors, including melanomas (Hanahan and
Weinberg, 2011). Melanoma cells elaborate a wide variety of
angiogenic factors in vitro, including VEGF, bFGF, IL-8, and
PDGF, and the importance of these mediators in promoting
melanoma angiogenesis and metastasis has been confirmed
in tumor xenotransplant models (Rofstad and Halsor, 2000).
Serum levels of VEGF in melanoma patients increase with
clinical stage, and high serum levels of VEGF represent an
adverse prognostic feature (Ugurel et al., 2001). On the basis
of these findings, several inhibitors of angiogenesis have been
tested in melanoma patients and some have demonstrated
activity against melanoma, including sunitinib (Chan et al.,
2008),vatalanib (Cook et al., 2010), axitinib (Fruehauf et al.,
2008), and aflibercept (Tarhini et al., 2009). Bevacizumab is
a humanized IgG antibody that binds to the most common
VEGF isoform, VEGF-A. Small studies of bevacizumab have
documented modest responses in conjunction with other
agents (Gonzalez-Cao et al., 2008; Perez et al., 2009;
Vihinen et al., 2010). One possible explanation is that
VEGF-A/VEGFR-2 blockade leads to transient vessel remo-
deling and normalization of the tumor vasculature. This
results in vessel stabilization and reduced vascular perme-
ability, which facilitates access of co-administered che-
motherapeutic drugs. Moreover, it has been shown that
exposure of melanoma cells to chemotherapy induces VEGF
overproduction, which, in turn, may allow melanoma cells to
evade cell death and acquire resistance. Most recently, a
multicenter Phase II trial of temozolomide and bevacizumab
for stage IV melanoma patients showed promising results
with an OS of 9.3 months and PFS of 4.2 months.
Interestingly, response rates were higher in patients with
BRAFV600E wild-type patients compared with those with
mutated tumors (Dummer et al., 2010; von Moos et al.,
2011). Other trials that have evaluated angiogenesis inhibi-
tors in combination with chemotherapy have reported mixed
results. In a randomized Phase II trial, patients with metastatic
melanoma received first-line treatment with the combination
of paclitaxel and carboplatin, with or without bevacizumab.
Despite some encouraging early results, this trial ultimately
failed to demonstrate a significant PFS and OS advantage
(O’Day et al., 2009). However, a similar Phase III trial adding
sorafenib instead of bevacizumab to the combination of
paclitaxel and carboplatin as a second-line treatment in
patients with unresectable melanoma did not show any
improvement in PFS or OS in the sorafenib group (Hauschild
et al., 2009).
Axitinib is an oral inhibitor of VEGFR-1,-2, and -3, c-KIT,
PDGFR-a, and PDGFR-b. In a Phase II study of 32 patients
with stage IV melanoma, treatment with axitinib resulted in
an overall response rate of 16%, a median PFS of 2.3 months,
and a median OS of 13 months (Fruehauf et al., 2008).
Dovitinib, an inhibitor of FGFR, VEGFR, PDGFR, and other
tyrosine kinases, has demonstrated clinical activity and
acceptable toxicity in a Phase I study in 19 patients with
advanced melanoma (Kim et al., 2008). Vatalanib (PTK787/
zk222584), an inhibitor of VEGFR-1,-2, and -3, has shown
efficacy in stabilizing metastatic melanoma in a Phase II study
(Corrie et al., 2008; Cook et al., 2010).
Targeting the immune system
Melanoma is one of the most immunogenic tumors, as
supported by the observed spontaneous regression of the
primary tumor, the prognostic significance of tumor infiltra-
tion by lymphocytes, and the detection of tumor antigen–-
specific antibodies in the peripheral blood of melanoma
patients (Lee et al., 1999). Immunological approaches that
have shown some activity in patients with advanced
melanoma include the use of high-dose IL-2 and IFN-a,
autologous and allogeneic cellular vaccines, or cytokines.
Furthermore, multiple novel immunomodulatory agents with
activity against melanoma are in development. However,
only recently was a clear survival benefit achieved by two
different immune-directed approaches in metastatic melano-
ma (Hodi et al., 2010). The first approach includes
ipilimumab, a fully human mAb against cytotoxic T-
lymphocyte antigen 4 (CTLA-4). CTLA-4 is a co-inhibitory
molecule that functions to regulate T-cell activation. In
resting T cells, CTLA-4 is expressed intracellularly; however,
upon T-cell activation, the protein is transported to the
immune synapse where effector T cell and the antigen-
presenting cell make physical contact. Monoclonal anti-
bodies that bind to CTLA-4 can block the interaction between
B7 and CTLA-4 and can enhance immune responses,
including antitumor immunity. A Phase III randomized trial
of ipilimumab with or without a gp100 peptide vaccine vs.
gp100 peptide vaccine alone in previously treated stage IV
melanoma patients showed an OS advantage in the
ipilimumab groups (hazard ratio for death in the comparison
with gp100 alone, 0.66; P¼0.003; Hodi et al., 2010). The
impact of ipilimumab therapy on OS was further supported in
a recent Phase III study of ipilimumab with dacarbazine vs.
dacarbazine alone in 502 previously untreated stage IV
melanoma patients. The trial showed a significant OS benefit
in the group receiving ipilimumab plus dacarbazine than in
the group receiving dacarbazine plus placebo (11.2 vs. 9.1
months), with higher survival rates in the ipilimumab–dacar-
bazine group at 1 year (47.3 vs. 36.3%), 2 years (28.5 vs.
17.9%), and 3 years (20.8 vs. 12.2%; Robert et al., 2011).
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After positive results in advanced disease, the adjuvant
role of ipilimumab has been examined in two studies:
EORTC18071, where ipilumimab is compared with placebo,
and ECOG E1609, where it is compared with high-dose
IFN-a. Finally, a trial of ipilimumab and vemurafenib
(NCT01400451) will be open in the near future for patients
with BRAFV600 mutations.
Programmed death-1 is an inhibitory receptor expressed
on activated T cells that also suppresses antitumor immunity.
Anti-programmed death-1 blockage is thus related to, but
distinct from, ipilimumab. In a Phase I trial, 39 patients with
advanced metastatic melanoma, colorectal cancer, prostate
cancer, non-small-cell lung cancer, or renal cell carcinoma
received a single intravenous infusion of anti-programmed
death-1 (0.3, 1, 3, or 10mg kg1), followed by a 15-patient
expansion cohort at 10mg kg1. One durable complete
response and two partial responses (melanoma, RCC) were
reported with anti-programmed death-1, although there was
one serious adverse event (inflammatory colitis) in a patient
with melanoma (Brahmer et al., 2010).
The second immune-targeted approach includes the
combination of high-dose IL-2 and the gp100:209–217
(210M) peptide vaccine vs. IL-2 alone. A Phase III trial
including 185 patients with advanced melanoma showed that
the vaccine/IL-2 group had a higher response rate (16 vs. 6%,
P¼0.03), and a 9% complete response rate in the vaccine/IL-
2 group vs. 1% in the IL-2 alone group. Median PFS (2.2 vs.
1.6 months; P¼0.008) and median OS (17.8 vs. 11.1
months; P¼ 0.06) were also improved (Schwartzentruber
et al., 2011).
These recent trials with immune-based therapies have
added tremendous balance to the pipeline of molecular
treatments that have emerged. One of the major advantages
of immunologically directed therapies is the application of
these treatments to patients who are ineligible for anti-BRAF
regimens. However, some immune-based approaches do
require specific host profiles, such as HLA haplotypes.
CONCLUSION
Melanoma remains the deadliest form of skin cancer and,
until recently, there have been only few therapeutic options
for patients with metastatic disease. At present, genotyping
metastatic tissue is of paramount importance as BRAF/c-KIT
status dictates the eligibility for treatment with vemurafenib
and imatinib, respectively. Although targeted therapies have
produced major clinical responses, their impact on OS and
cures is still under investigation. It is now clear that
melanoma is not a singular, homogeneous disease with a
common set of genetic alterations. Hence, the selection of
treatment will likely be dictated by distinct molecular
signatures. Future efforts will need to focus on targeting
multiple coexistent aberrations in different pathways, and
addressing the mechanisms that underlie the tumor’s
propensity for growth and chemoresistance. The greatest
challenge lies in the elucidation of mechanisms by which
resistance develops. This in turn will lead to a rational basis
for combination therapy or second-generation agents aimed
at circumventing resistance.
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